Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "CNS-therapeutics"

4 News Found

Terran Biosciences acquires Concert’s CNS therapeutics portfolio
News | March 12, 2022

Terran Biosciences acquires Concert’s CNS therapeutics portfolio

These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed

Exciva initiates Phase 2/3 SERENADA trial for Alzheimer’s agitation therapy
Clinical Trials | April 29, 2026

Exciva initiates Phase 2/3 SERENADA trial for Alzheimer’s agitation therapy

The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
Drug Approval | October 11, 2025

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults

Terran Biosciences announces licensing deal with Sanofi
Biotech | April 22, 2022

Terran Biosciences announces licensing deal with Sanofi

Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics

Latest Stories

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Leinco Technologies and CellCarta partner to advance proteomics in immuno-oncology

Sanofi Consumer Healthcare reports 33% revenue growth in Q1 FY26; PAT rises 36%

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Betting on NK-cell innovation and combination immunotherapy to build global clinical-stage biotech: Dr Maloy Ghosh, CSO, Zumutor Biologics
Dr Maloy Ghosh Chief Scientific Officer, Zumutor Biologics
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
The next big opportunity lies in immune and rare disease white spaces: Venkat Nelabhotla, President & CEO, Vyome Holdings
Venkat Nelabhotla Co-Founder, President & CEO, Vyome Holdings, Inc.
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Head Bioprocessing, India, Avantor

Packaging